Item 1. Legal Proceedings
ITEM 1. Legal Proceedings
The Company is subject to legal proceedings and
claims that have arisen in the ordinary course of business. Our management evaluates our exposure to these claims and proceedings individually
and in the aggregate and evaluates potential losses on such litigation if the amount of the loss is estimable and the loss is probable.
However, the outcome of legal proceedings and claims brought against the Company is subject to significant uncertainty. Although management
considers the likelihood of such an outcome to be remote, if one or more of these legal matters were resolved against the Company for
amounts in excess of management’s expectations, the Company’s financial statements for that reporting period could be materially
adversely affected.
In 2017, the Company’s former COO was awarded
approximately $238,000 in accrued salary and related charges by the California labor board. In August 2021, the Company reached a settlement
by which the Company agreed to pay approximately $330,000, representing the principal award plus accrued interest. As of the time of
this filing, the Company has paid approximately $187,000 toward the settlement amount. The remaining balance of approximately $171,000
is to be paid no later than March 1, 2023, and accrues interest of 10% per annum until paid.
Since July 2017 the Company has been engaged
in litigation with a former director, Robert Kopple, relating to more than $13 million and the current equivalent of the approximately
23 million warrants, exercisable for seven years at a price of $0.10 per share, which Mr. Kopple and his affiliated entities (collectively
the “Kopple Parties”) claimed should have been originally issued to them pursuant to various agreements with the Company
entered to between 2013-2016. In March 2022, the Company reached a settlement with the Kopple Parties that resolves all claims asserted
against the Company without any admission, concession or finding of any fault, liability or wrongdoing on the part of the Company. Under
the terms of the settlement, we have agreed to pay an aggregate amount of $10 million over a period of seven years; $3 million of which
was originally to be paid in June 2022, and subsequently amended to extend the initial installment to January 2023, after which, interest
will accrue on the unpaid balance at a rate of 6%, compounded annually. All amounts, including all accrued interest, are to be paid no
later than eight years from the date of the initial payment. The Kopple Parties have also received seven-year warrants to purchase up
to an aggregate of approximately 3.3 million shares of our common stock at a price of $0.85 per share. The settlement also provides for
standard mutual general release provisions and includes customary representations, warranties, and covenants, including certain increases
in the amount payable to the Kopple Parties and the right of such parties to enter judgment against the Company if the Company remains
in uncured default in its payment obligations under the settlement. As of the date of this report, the Company has not yet paid the full
$3,000,000 installment due to Kopple; having made a partial payment of $150,000 in June 2022.
In March 2019, various stockholders of the Company
controlling a combined total of more than 27.5 million shares delivered signed written consents to the Company removing Ronald Buschur,
William Anderson, and Si Ryong Yu as directors of the Company’s Board and electing Cipora Lavut, David Mann and Dr. Robert Lempert
as directors in their stead. These written consents represented a majority of the then-outstanding shares of the Company’s
common stock. Because of the refusal by not only the removed directors but also Aura’s prior management to recognize the legal
effectiveness of the consents, in April 2019 the stockholders filed suit in the Court of Chancery of the State of Delaware pursuant
to Section 225 of the Delaware General Corporations Law, seeking an order confirming the validity of the consents. On July 8, 2019
the Court of Chancery entered final judgment in favor of the stockholder plaintiffs, confirming that (a) Ronald Buschur, Si Ryong Yu
and William Anderson had been validly removed by the holders of a majority of the Company’s outstanding stock acting by written
consent (b) Ms. Lavut, Mr. Mann and Dr. Lempert had been validly elected by the holders of a majority of the Company’s outstanding
stock acting by written consent, and (c) the Company’s Board of Directors validly consists of Cipora Lavut, David Mann, Robert
Lempert, Gary Douglas and Salvador Diaz-Versón, Jr. As a result of prior management’s unsuccessful opposition to this stockholders’
action filed in the Court of Chancery, such stockholders may be potentially entitled to recoup their litigation costs from the Company
under Delaware’s corporate benefit doctrine and/or other legal provisions. To date, no final determination has been made as to
the amount of recoupment, if any, to which such stockholders may be entitled.
30
In June 2022, Melvin
Gagerman, the Company’s former CEO and CFO whose employment with Aura was permanently terminated in July 2019, brought suit against
the Company for repayment of an allegedly unsecured demand promissory note in the principal amount of $82,000 which he claims was entered
into in April 2014 and bears interest at a rate of 10% per annum. Despite the fact that, based on Gagerman’s allegations, the note
was issued during a period when he was the Company’s CEO, CFO, Corporate Secretary and Chairman of Aura’s Board of Directors,
Gagerman has stated that he does not possess a copy of the alleged promissory note. The Company disputes that any amount is presently
owed to Gagerman and has filed a cross-complaint against him for, among things, conversion, violation of California Business& Professions
Code §17200, and various breaches of fiduciary duty that the Company believes Gagerman committed against Aura, including without
limitation, Gagerman’s actions in opposing the valid 2019 stockholder consent action.
ITEM 1A. Risk Factors
In addition to the other information set forth
in this report, you should carefully consider the risk factors disclosed in Item 1A, “Risk Factors,” of the Company’s
Fiscal 2022 Annual Report on Form 10-K issued on June 21, 2022.
Text extracted from the filing as submitted to EDGAR. Formatting, tables and exhibits are simplified for reading; the original document is authoritative for anything you rely on.